In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...

Compass will now seek approval for COMP360 in TRD, which could become the first classic psychedelic to gain the FDA’s ...

Teva Pharmaceuticals and Sanofi’s monoclonal antibody (mAb) has shown durable clinical and endoscopic efficacy in a Phase IIb ...

The North Midlands CRDC has recruited its first patient, representing the UK’s initial participation in a clinical trial of ...

Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.

Clinical trials are facing new and evolving challenges as costs increase and approval timelines remain lengthy. Modernisation ...

As the oral weight loss drug market has started to emerge, AstraZeneca has told shareholders that it will advance its ...

Another of Pfizer’s Braftovi regimens has shown benefit in patients with previously untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation.

CStone Pharmaceuticals' IND application has received FDA clearance, enabling the company to initiate a Phase II trial of its trispecific antibody CS2009.

Evommune’s potential Dupixent competitor has met its primary endpoint in a Phase IIa atopic dermatitis (AD) trial, achieving a 33% reduction in Eczema Area and Severity Index (EASI).

This comes as Upstream Bio's twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing severe asthma exacerbations.

Nektar will now take Treg therapy, rezpeg to a Phase III trial in atopic dermatitis (AD), which is set to begin in Q2 2026.